Modeyso™ (dordaviprone) – New orphan drug approval
August 6, 2025 - The FDA announced the approval of Jazz Pharmaceuticals’ Modeyso (dordaviprone), for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.